Related Experiment Video
Updated: May 1, 2026
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Coleusin factor, a novel anticancer diterpenoid, inhibits osteosarcoma growth by inducing bone morphogenetic
1Authors' Affiliations: State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Graduate University of Chinese Academy of Sciences; Department of Biology, Capital Normal University, Beijing, China; and Department of Biological Sciences, Virginia Tech, Blacksburg, VirginiaAuthors' Affiliations: State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Graduate University of Chinese Academy of Sciences; Department of Biology, Capital Normal University, Beijing, China; and Department of Biological Sciences, Virginia Tech, Blacksburg, VirginiaAuthors' Affiliations: State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Graduate University of Chinese Academy of Sciences; Department of Biology, Capital Normal University, Beijing, China; and Department of Biological Sciences, Virginia Tech, Blacksburg, Virginia.
Abstract:
Coleusin factor is a diterpenoid compound isolated from the root of a tropical plant, Coleus forskohlii. Although Coleusin factor has been reported to suppress proliferation of and induce apoptosis in several types of cancer cells, the effects of Coleusin factor on osteosarcoma and the underlying mechanism are still not fully understood. In this study, we show that Coleusin factor treatment potently inhibits the growth of osteosarcoma cells associated with G(1) cell-cycle arrest. Interestingly, apoptosis and cell death are not induced. Instead, Coleusin factor causes osteosarcoma cells to exhibit typical properties of differentiated osteoblasts, including a morphologic alteration resembling osteoblasts, the expression of osteoblast differentiation markers, elevated alkaline phosphatase activity, and increased cellular mineralization. Coleusin factor treatment significantly increases the expression of bone morphogenetic protein-2 (BMP-2), a crucial osteogenic regulator, and runt-related transcription factor 2 (RUNX2), one of the key transcription factors of the BMP pathway. When BMP-2 signaling is blocked, Coleusin factor fails to inhibit cell proliferation and to induce osteoblast differentiation. Thus, upregulation of BMP-2 autocrine is critical for Coleusin factor to induce osteoblast differentiation and exert its anticancer effects on osteosarcoma. Importantly, administration of Coleusin factor inhibits the growth of osteosarcoma xenografted in nude mice without systemic or immunologic toxicity. Osteosarcoma is a highly aggressive cancer marked by the loss of normal differentiation. Coleusin factor represents a new type of BMP-2 inducer that restores differentiation in osteosarcoma cells. It may provide a promising therapeutic strategy against osteosarcoma with minimal side effects.
Insights
Coleusin factor, a plant compound, halts osteosarcoma growth by promoting cell differentiation, not apoptosis. This novel therapeutic strategy restores normal bone cell characteristics with minimal toxicity.
Area of Science:
- Molecular Biology
- Cancer Research
- Pharmacology
Background:
- Osteosarcoma is an aggressive bone cancer characterized by loss of normal cell differentiation.
- Coleusin factor, a diterpenoid from Coleus forskohlii, shows anti-cancer properties but its mechanism in osteosarcoma is unclear.
- Previous studies suggest Coleusin factor suppresses cancer cell proliferation and induces apoptosis.
Purpose of the Study:
- To investigate the effects of Coleusin factor on osteosarcoma cell growth and differentiation.
- To elucidate the underlying molecular mechanisms of Coleusin factor's action in osteosarcoma.
- To evaluate the therapeutic potential of Coleusin factor against osteosarcoma in vivo.
Main Methods:
- Osteosarcoma cells were treated with Coleusin factor.
- Cell proliferation, cell-cycle arrest, apoptosis, and osteoblast differentiation markers were assessed.
- Bone morphogenetic protein-2 (BMP-2) and runt-related transcription factor 2 (RUNX2) expression and signaling were analyzed.
- Osteosarcoma xenograft models in nude mice were used to evaluate in vivo efficacy and toxicity.
Main Results:
- Coleusin factor inhibited osteosarcoma cell growth by inducing G1 cell-cycle arrest, without inducing apoptosis.
- Osteosarcoma cells treated with Coleusin factor exhibited osteoblast differentiation markers, increased alkaline phosphatase activity, and mineralization.
- Coleusin factor upregulated BMP-2 and RUNX2 expression; blocking BMP-2 signaling abrogated Coleusin factor's effects.
- In vivo administration of Coleusin factor inhibited osteosarcoma xenograft growth without significant toxicity.
Conclusions:
- Coleusin factor promotes osteosarcoma cell differentiation into osteoblasts via BMP-2/RUNX2 pathway activation.
- Upregulation of BMP-2 autocrine signaling is critical for Coleusin factor's therapeutic effects.
- Coleusin factor represents a promising therapeutic agent for osteosarcoma by restoring normal cell differentiation with minimal side effects.
Related Concept Videos
02:23Abnormal Proliferation
02:38Mitogens and the Cell Cycle